Plain-English translation of NCT06655389 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a blood marker called PLA (platelet-leukocyte aggregates) to see if it can predict how severe heart problems become in patients with sepsis — a life-threatening infection. When sepsis develops, it can damage the heart and reduce its ability to pump effectively. This research hopes to find out whether measuring PLA levels in the blood could help doctors better understand and treat sepsis-related heart failure.
Sepsis with heart complications is a serious condition with high death rates, but doctors don't have reliable ways to measure how severe the heart damage is or predict patient outcomes. This study seeks to discover whether this blood marker could become a useful tool for evaluating and guiding treatment of sepsis-related heart problems.
You likely qualify if…
You likely don't qualify if…
As a participant, you would have a blood sample drawn to measure PLA levels and other markers related to your heart and immune system. The study also involves comparing your clinical information (such as heart ultrasound findings and cardiac injury markers) with the blood results. This is an observational study, meaning researchers are watching and measuring rather than giving a new treatment — your regular sepsis care would continue as planned by your hospital team.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
China
Sponsor
Dongzhimen Hospital, Beijing
Enrollment target
~30 participants
Started
May 2024
Primary completion
December 2026
Age range
50 Years – 90 Years
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yao Sheng Xiu
DongzhimenH，Beijing
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.